---
title: "Humacyte names nephrologists Kossmann, Roy-Chaudhury as dialysis access advisors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292622452.md"
description: "Humacyte appointed nephrologists Robert J. Kossmann and Prabir Roy-Chaudhury as advisors to support the commercialization of its acellular tissue-engineered vessel (ATEV) for hemodialysis access. The experts will focus on reimbursement, market access, health economics, and medical education. This appointment follows positive Phase 3 results for the V012 product in women and precedes plans to file a supplemental Biologic License Application."
datetime: "2026-07-14T12:07:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292622452.md)
  - [en](https://longbridge.com/en/news/292622452.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292622452.md)
---

# Humacyte names nephrologists Kossmann, Roy-Chaudhury as dialysis access advisors

-   Humacyte named nephrologists Robert J. Kossmann and Prabir Roy-Chaudhury as advisors to support planned commercialization of its ATEV for hemodialysis access. \* Kossmann previously held senior medical leadership roles at Fresenius Medical Care from 2014-2026, including executive vice president and chief medical officer for North America. \* Roy-Chaudhury is the Drs. Ronald and Katherine Falk Eminent Professor at UNC, co-directs the UNC Kidney Center, and served as American Society of Nephrology president for 2025. \* The advisors will focus on reimbursement, market access, health economics, and medical education tied to the dialysis access opportunity. \* The move follows positive V012 Phase 3 results in women and plans to file a supplemental Biologic License Application. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [HUMA.US](https://longbridge.com/en/quote/HUMA.US.md)
- [FMS.US](https://longbridge.com/en/quote/FMS.US.md)
- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)
- [FME.DE](https://longbridge.com/en/quote/FME.DE.md)

## Related News & Research

- [Humacyte says Phase 3 V007 trial results show ATEV tops fistula for hemodialysis access at one year](https://longbridge.com/en/news/296352370.md)
- [Is Humacyte (HUMA) Undervalued Following Q2 2026 Earnings And Dialysis Trial Data?](https://longbridge.com/en/news/295760868.md)
- [Humacyte (HUMA) Q2 2026 Earnings Call: Dialysis sBLA Targeted for November](https://longbridge.com/en/news/295902187.md)
- [Humacyte Faces Nasdaq Non-Compliance Warning as Share Price Risks Delisting and Future Capital Constraints](https://longbridge.com/en/news/295900197.md)
- [Humacyte Q2 net loss widens on inventory, production costs](https://longbridge.com/en/news/295655400.md)